Dr. Htut on CAR T-Cell Therapy in Patients With Multiple Myeloma
Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.
Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.
City of Hope now has 2 different protocols for the use of CAR T-cell therapy in patients with multiple myeloma. First is the BCMA-targeted therapy protocol from Juno therapeutics. The second protocol is high-affinity T-cell receptor targeting NY-ESO-1/HLA-A. Both are active and currently enrolling patients. Physicians at City of Hope also plan to have a homegrown CAR T-cell therapy targeting CS1. The study will be led by Htut, the principal investigator, pending FDA approval.
There are other potential targets including CD44v6, CD8, and CD138. Physicians are also looking to combine a T cell that can target CS1 as well as BCMA.
